Samsung Bioepis says it has moved ahead with its proposed biosimilar version of Alexion’s Soliris (eculizmab) after the joint venture between Samsung Biologics and Biogen completed a Phase III clinical trial for its SB12 candidate.
“The Phase III clinical trial for SB12 has been completed as of 21 October 2021,”a Samsung Bioepis spokesperson confirmed to...






